Skip to content

Evaluation of immunostimulatory effects of test food intake

Evaluation of immunostimulatory effects of test food intake - Evaluation of immunostimulatory effects of test food intake

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000041340
Enrollment
20
Registered
2020-08-17
Start date
2020-08-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intake 5 capsules those contain test food three times a day (after each meal), for 8 weeks. Intake 5 capsules those contain no test food three times a day (after each meal), for 8 weeks.

Sponsors

CPCC Company Limited
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1)Males and females aged 30 to 49 at resistration. 2)Subjects giving written informed consent.

Exclusion criteria

Exclusion criteria: 1) Subjects who constantly use medicines, supplements having a possibility of affecting test results. 2) Subjects who have previous and/or current medical history of serious disease such a the heart, liver, kidneys, gastrointestinal tract, etc. 3) Subjects who excessive alcohol intake. 4) Subjects who excess smoker. 5) Subjects who have extremely irregular dining habits, and subjects who have midnight work or irregular shift work. 6) Subjects who have previous medical history of drug and/or food (especially gelatin) allergy. 7) Subjects who are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests. 8) Subjects who donated over 200mL blood and/or blood components within the last one month to the current study. 9) Males who donated over 400mL blood and/or blood components within the last three month to the current study. 10)Males who will be collected over 1200mL blood and/or blood components, when the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. 11) Subjects who are positive for infectious. 12) Others who have been determined ineligible by principal investigator or sub-investigator.

Design outcomes

Primary

MeasureTime frame
blood IgA blood IgG

Secondary

MeasureTime frame
NK cell activity

Countries

Japan

Contacts

Public ContactMakoto Ichinohe

CPCC Company Limited Sales & Planning Department

cpcc-contact@cpcc.co.jp03-5927-3112

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026